GRTS Gritstone Oncology Inc.

7.09
+0.8  (+13%)
Previous Close 6.29
Open 6.48
52 Week Low 5.42
52 Week High 12.96
Market Cap $264,208,545
Shares 37,264,957
Float 24,155,031
Enterprise Value $149,038,579
Volume 1,536,532
Av. Daily Volume 325,128
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SLATE-001
Solid tumors
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
GRANITE-001 (GO-004)
Solid tumors
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. EMERYVILLE, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the Gritstone management team will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET to present data from the ongoing Phase 1 studies of its immunotherapy product candidates GRANITE and SLATE. Phase 2 study plans will also be discussed.

    Daniel Catenacci, M.D., director of the gastrointestinal oncology program and assistant director of translational research at the Comprehensive Cancer Center in the University of Chicago, will be a featured speaker.  He is a principal investigator…

    EMERYVILLE, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the Gritstone management team will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET to present data from the ongoing Phase 1 studies of its immunotherapy product candidates GRANITE and SLATE. Phase 2 study plans will also be discussed.

    Daniel Catenacci, M.D., director of the gastrointestinal oncology program and assistant director of translational research at the Comprehensive Cancer Center in the University of Chicago, will be a featured speaker.  He is a principal investigator on both clinical trials.

    To participate in the teleconference, please dial (866) 939-3921 (domestic) or (678) 302-3550 (international) and refer to conference ID 49783015. Live audio of the teleconference and accompanying slides will be simultaneously webcast and will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.

    About Gritstone Oncology

    Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's "off the shelf" shared neoantigen-based immunotherapy, SLATE, and its individualized neoantigen-based immunotherapy, GRANITE, are being evaluated in Phase 1 clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

    Contacts

    Media:

    Dan Budwick

    1AB

    (973) 271-6085

    Investors:

    Alexandra Santos

    Wheelhouse Life Science Advisors

    (510) 871-6161

    a.com

    Primary Logo

    View Full Article Hide Full Article
  2. EMERYVILLE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer of Gustave Roussy Cancer Center, has joined the company's scientific advisory board (SAB).

    "We are delighted that our co-founder Jean-Charles, a world-class medical oncologist and scientist, has rejoined our SAB following his tenure at AstraZeneca," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. "Jean-Charles' deep oncology expertise and fresh experience in strategic portfolio analysis and…

    EMERYVILLE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer of Gustave Roussy Cancer Center, has joined the company's scientific advisory board (SAB).

    "We are delighted that our co-founder Jean-Charles, a world-class medical oncologist and scientist, has rejoined our SAB following his tenure at AstraZeneca," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. "Jean-Charles' deep oncology expertise and fresh experience in strategic portfolio analysis and expansion will be invaluable as we maximize the potential of our development programs and our foundational proprietary technologies, such as our artificial intelligence platform Gritstone EDGE™."

    Dr. Soria is the chief executive officer of Gustave Roussy Cancer Center, the premier European comprehensive cancer center based in Villejuif, France, a position to which he was appointed in January 2020. Previously, he was the senior vice president of early oncology research and development for AstraZeneca where he oversaw strategic planning and clinical development for product candidates in immuno-oncology, including cell therapy and antibody drug conjugates. Since 2006, Jean-Charles has been a tenured professor of medicine and medical oncology at the Université Paris Sud, and created and led the Drug Development Department (DITEP) at the Gustave Roussy Cancer Center where he conducted or supervised more than 50 Phase 1 studies in targeted therapies and immunotherapies against cancer.

    Dr. Soria trained as a medical oncologist at the Université René Descartes in Paris, France, where he received his M.D. and obtained the prestigious Silver Medal from Paris Residency Hospitals in 1997. He received his Ph.D. in 2001 from Université Paris Sud, also in Paris, following innovative translational research in targeted therapies, and conducted a two-year post-doctoral fellowship in the department of thoracic head and neck medical oncology at MD Anderson Cancer Center, in Houston, USA, where he held an Adjunct Professorship from 2012 to 2017. Dr. Soria has contributed to over 640 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology. From 2014 to 2017, he was editor in chief of the Annals of Oncology.

    Dr. Soria added, "The capacity of the immune system to identify and kill tumor cells, leading to durable clinical benefit, is abundantly clear to us all. Understanding and harnessing the mechanisms underlying these phenomena is a key contemporary challenge in oncology therapeutics. As they come to the end of Phase 1 clinical trials for their lead programs, Gritstone's opportunity to apply their scientific insights to the treatment of patients with solid tumor cancers, particularly in the early stage context, is unique. I am thrilled to join the SAB during this exciting time."

    About Gritstone Oncology

    Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's "off the shelf" shared neoantigen-based immunotherapy, SLATE, and its individualized neoantigen-based immunotherapy, GRANITE, are being evaluated in Phase 1 clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

    Gritstone Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone's therapeutic programs. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone's most recent Quarterly Report on Form 10-Q filed on May 7, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.

    Contacts

    Media:

    Dan Budwick

    1AB

    (973) 271-6085





    Investors:

    Alexandra Santos

    Wheelhouse Life Science Advisors

    (510) 871-6161

    Primary Logo

    View Full Article Hide Full Article
  3. EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview at two upcoming investor conferences in June.

    • Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 2:10 p.m. ET
    • Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ET

    A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived…

    EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview at two upcoming investor conferences in June.

    • Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 2:10 p.m. ET
    • Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ET

    A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.

    About Gritstone Oncology
    Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's "off the shelf" shared neoantigen-based immunotherapy, SLATE, and its individualized neoantigen-based immunotherapy, GRANITE, are being evaluated in Phase 1 clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

    Contacts
    Media:
    Dan Budwick
    1AB
    (973) 271-6085

    Investors:
    Alexandra Santos
    Wheelhouse Life Science Advisors
    (510) 871-6161

    Primary Logo

    View Full Article Hide Full Article
  4. EMERYVILLE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the first quarter ended March 31, 2020 and reviewed business highlights.

    "We began this year by presenting the first-ever clinical data of its kind, demonstrating that an immunotherapy can prime and boost a strong CD8+ T cell response against tumor-specific neoantigens," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. "The early clinical results from our Phase 1 studies of GRANITE and SLATE are another critical step towards our ultimate…

    EMERYVILLE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the first quarter ended March 31, 2020 and reviewed business highlights.

    "We began this year by presenting the first-ever clinical data of its kind, demonstrating that an immunotherapy can prime and boost a strong CD8+ T cell response against tumor-specific neoantigens," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. "The early clinical results from our Phase 1 studies of GRANITE and SLATE are another critical step towards our ultimate goal of broadening the clinical benefits of immunotherapy for patients with solid tumors. We will host a webcasted investor event mid-year to present updated data from these trials. Since the company's inception in 2015, we have built a best-in-class neoantigen prediction capability (Gritstone EDGETM); we have designed a potent novel vaccine vector system to prime and boost strong CD8+ T cell responses in humans to encoded neoantigens; we have established a state-of-the-art biomanufacturing facility; and we have now shown in early Phase 1 studies in patients with end-stage disease that this biology can be successfully and safely deployed. We are very close to initiating phase 2 trials in patients with less advanced disease where we expect neoantigen-directed immunotherapy to exhibit greatest clinical benefit. The adjuvant opportunities are particularly exciting given the power of new technologies that measure circulating tumor DNA to identify patients at very high risk of disease recurrence after attempted curative surgical therapy. We have several Phase 2 study initiations expected to occur over the next 12 months, and while we currently anticipate nominal impact from COVID-19 on our trial timelines, we are monitoring this situation closely. As an organization, we have strengthened our operations with the expansion of our in-house manufacturing capabilities and the appointment of additional experienced executives to our team. Finally, we expect that our cash position will support our important development work through key program milestones into the third quarter of 2021."

    Recent Accomplishments

    • Reported early immunogenicity, safety and efficacy data from a Phase 1 study evaluating GRANITE, an individualized product candidate, in combination with immune checkpoint blockade for the treatment of patients with advanced solid tumors, including microsatellite stable colorectal cancer (MSS-CRC), gastroesophageal cancer, metastatic non-small cell lung cancer (NSCLC), and bladder cancer
    • Reported the same data types from a Phase 1 study evaluating SLATE, an off-the-shelf targeted immunotherapy product candidate, in combination with immune checkpoint blockade for the treatment of patients with metastatic NSCLC, pancreatic ductal adenocarcinoma and MSS-CRC, as well as in patients with other solid tumor types who have relevant mutation/human leukocyte antigen (HLA) combinations
    • Appointed Rahsaan W. Thompson, J.D., veteran legal executive with over 20 years of corporate counsel experience, as executive vice president and general counsel
    • Appointed Elaine V. Jones, Ph.D., an existing board member, to the position of chairman of the board of directors
    • Internalized additional manufacturing operations for the production of SLATE and GRANITE immunotherapies at Gritstone's ~43,000 sq. ft. fully integrated GMP biomanufacturing facility in Pleasanton, California

    Anticipated Upcoming Milestones

    • Present additional efficacy and safety data from the Phase 1 studies of SLATE and GRANITE in a company-hosted webcast event in mid-2020
    • Initiate Phase 2 expansion cohorts in the second half of 2020
    • Initiate Phase 2 adjuvant study/studies in early 2021
    • Nominate a lead bispecific antibody development candidate directed towards a novel solid tumor-specific HLA-peptide complex in the second half of 2020

    First Quarter 2020 Financial Results
    For the three months ended March 31, 2020, Gritstone reported a net loss of $26.2 million, compared to a net loss of $18.0 million for the three months ended March 31, 2019.

    Collaboration revenue was $1.3 million for the three months ended March 31, 2020, compared to $1.3 million for the three months ended March 31, 2019. Collaboration revenue was due to the Research Collaboration and License Agreement with bluebird bio Inc. and another small collaboration agreement.

    Total research and development expenses were $22.5 million for the three months ended March 31, 2020, compared to $15.9 million for the three months ended March 31, 2019. The increase was primarily attributable to an increase in personnel-related expenses driven by increased headcount, as well as an increase in outside services and consultants, in-house laboratory supplies and consumables, and facilities-related expenses.

    General and administrative expenses were $5.5 million for the three months ended March 31, 2020, compared to $4.4 million for the three months ended March 31, 2019. The increase was primarily attributable to an increase in personnel-related expenses driven by an increase in headcount and an increase in legal and other outside professional services required to support the company's ongoing operations as a public company.

    Cash, cash equivalents, marketable securities and restricted cash were $109.9 million as of March 31, 2020, compared to $128.8 million as of December 31, 2019.

    About Gritstone Oncology
    Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's "off the shelf" shared neoantigen-based immunotherapy, SLATE, and its individualized neoantigen-based immunotherapy, GRANITE, are being evaluated in Phase 1 clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

    Gritstone Forward-Looking Statements
    This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone's therapeutic programs; the advancements in the Company's ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials, including the timing thereof. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone's most recent Quarterly Report on Form 10-Q filed on May 7, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.

    Contacts
    Media:
    Dan Budwick
    1AB
    (973) 271-6085

    Investors:
    Alexandra Santos
    Wheelhouse Life Science Advisors
    (510) 871-6161

     
    Gritstone Oncology, Inc.
    Condensed Statements of Operations
    (Unaudited)
    (In thousands, except share and per share data)
             
        Three Months Ended
        March 31,
             
          2020       2019  
             
             
    Collaboration revenue   $ 1,262     $ 1,347  
             
    Operating expenses:        
    Research and development   $ 22,468       15,899  
    General and administrative   $ 5,465       4,377  
    Total operating expenses     27,933       20,276  
    Loss from operations     (26,671 )     (18,929 )
    Interest and other income, net   $ 465       920  
    Net loss   $ (26,206 )   $ (18,009 )
    Net loss per common share, basic and diluted   $ (0.71 )   $ (0.62 )
    Shares used to compute for net loss per common share, basic and diluted     36,798,562       28,938,891  
             


    Gritstone Oncology, Inc.
    Condensed Balance Sheets
    (Unaudited)
    (In thousands)
             
        March 31,
    2020
      December 31,
    2019
             
    Assets        
    Current assets:        
    Cash and cash equivalents   $ 54,860     $ 57,408  
    Marketable securities     54,020       70,368  
    Prepaid expenses and other current assets     3,466       3,497  
    Total current assets     112,346       131,273  
    Property and equipment, net     25,847       26,911  
    Operating lease right-of-use assets     22,130       23,427  
    Deposits and other long-term assets     2,695       2,778  
    Total assets   $ 163,018     $ 184,389  
             
    Liabilities and stockholders' equity        
    Current liabilities:        
    Accounts payable   $ 5,008     $ 4,621  
    Accrued compensation     2,775       4,598  
    Accrued liabilities     414       1,041  
    Accrued research and development     2,311       1,779  
    Lease liabilities, current portion     3,421       2,505  
    Deferred revenue, current portion     4,511       4,956  
    Total current liabilities     18,440       19,500  
    Lease liabilities, net of current portion     20,101       20,985  
    Deferred revenue, net of current portion     9,088       9,560  
    Total liabilities     47,629       50,045  
    Commitments and contingencies        
    Stockholders' equity:        
    Convertible preferred stock     -       -  
    Common stock     17       17  
    Additional paid-in capital     362,586       355,291  
    Accumulated other comprehensive loss     (20 )     24  
    Accumulated deficit     (247,194 )     (220,988 )
    Total stockholders' equity     115,389       134,344  
    Total liabilities and stockholders' equity   $ 163,018     $ 184,389  
             

    Primary Logo

    View Full Article Hide Full Article
  5. EMERYVILLE, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the appointment of Elaine V. Jones, Ph.D., as chair of the board of directors.

    "Elaine has been a very strong addition to our board, as reflected in the unanimous vote to appoint her to the position of board chair," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. "She has made significant contributions towards advancing our current programs, including our existing cancer neoantigen-based immunotherapies and bispecific antibodies, as well as in our evaluation…

    EMERYVILLE, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the appointment of Elaine V. Jones, Ph.D., as chair of the board of directors.

    "Elaine has been a very strong addition to our board, as reflected in the unanimous vote to appoint her to the position of board chair," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. "She has made significant contributions towards advancing our current programs, including our existing cancer neoantigen-based immunotherapies and bispecific antibodies, as well as in our evaluation of additional portfolio expansion opportunities. Her scientific and business acumen, as well as her extensive experience in shaping innovative biotechs, will be invaluable to Gritstone as we pioneer entirely novel classes of products based on our deep understanding of T cells and T cell targets."

    Dr. Jones was most recently vice president, worldwide business development and senior partner at Pfizer Ventures, the corporate venture capital arm of Pfizer Inc. During her tenure from 2008 to 2019, Dr. Jones was responsible for managing biotechnology and healthcare investments for Pfizer, as well as serving on the board of directors for several biotechnology companies. Prior to this, Dr. Jones held the position of general partner at EuclidSR Partners, a venture firm specializing in private investment in both private and public equity within the health sciences, healthcare, biopharmaceutical sectors. Dr. Jones began her investing career in 1999 at S.R. One, the corporate investment fund of GlaxoSmithKline. During her venture career, she served on the boards of more than 20 early to mid-stage biotechnology, therapeutic and pharmaceutical companies. Previously, Dr. Jones was the director of scientific licensing at SmithKline Beecham and a research scientist in the research and development division of SmithKline Beecham Pharmaceuticals. She received a B.S. in biology from Juniata College and a Ph.D. in microbiology from the University of Pittsburgh.

    Dr. Jones added, "It has been a pleasure to serve on the board of directors for Gritstone, a company that had the vision to become a leader in neoantigen and tumor antigen discovery and is now administering pioneering immunotherapies utilizing these T cell targets in cancer patients. I am honored to be appointed as chair and look forward to working closely with the board and Gritstone's leadership team to continue the company's positive momentum in our pursuit of bringing novel cancer treatments to patients."

    About Gritstone Oncology
    Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's "off the shelf" shared neoantigen-based immunotherapy, SLATE, and its individualized neoantigen-based immunotherapy, GRANITE, are being evaluated in Phase 1 clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

    Gritstone Forward-Looking Statements
    This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone's therapeutic programs. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone's most recent Annual Report on Form 10-K filed on March 11, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.

    Contacts
    Media:
    Dan Budwick
    1AB
    (973) 271-6085

    Investors:
    Alexandra Santos
    Wheelhouse Life Science Advisors
    (510) 871-6161

    Primary Logo

    View Full Article Hide Full Article
View All Gritstone Oncology Inc. News